339 related articles for article (PubMed ID: 15592807)
1. [Apomorphine in the treatment of Parkinson's Disease].
Dressler D
Nervenarzt; 2005 Jun; 76(6):681-9. PubMed ID: 15592807
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
Deleu D; Hanssens Y; Northway MG
Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
[TBL] [Abstract][Full Text] [Related]
3. [Apomorphine in off state--clinical experience].
Rudzińska M; Szczudlik A
Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S40-8. PubMed ID: 17941458
[TBL] [Abstract][Full Text] [Related]
4. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
Colzi A; Turner K; Lees AJ
J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668
[TBL] [Abstract][Full Text] [Related]
5. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
6. Clinical insights into use of apomorphine in Parkinson's disease: tools for clinicians.
Henriksen T
Neurodegener Dis Manag; 2014; 4(3):271-82. PubMed ID: 25095821
[TBL] [Abstract][Full Text] [Related]
7. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
Zoldan J; Merims D; Kuritzky A; Ziv I; Melamed E
Harefuah; 1999 Nov; 137(10):444-6, 512, 511. PubMed ID: 10959339
[TBL] [Abstract][Full Text] [Related]
8. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
Manson AJ; Turner K; Lees AJ
Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
[TBL] [Abstract][Full Text] [Related]
9. Apomorphine in patients with Parkinson's disease.
Muguet D; Broussolle E; Chazot G
Biomed Pharmacother; 1995; 49(4):197-209. PubMed ID: 7669939
[TBL] [Abstract][Full Text] [Related]
10. [Apomorphine in treatment of Parkinson's disease with fluctuations].
Zaleska B; Domzał T
Neurol Neurochir Pol; 1999; 33(6):1297-303. PubMed ID: 10791032
[TBL] [Abstract][Full Text] [Related]
11. Practical considerations in the use of apomorphine injectable.
Bowron A
Neurology; 2004 Mar; 62(6 Suppl 4):S32-6. PubMed ID: 15037670
[TBL] [Abstract][Full Text] [Related]
12. Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study.
Borgemeester RWK; van Laar T
Parkinsonism Relat Disord; 2017 Dec; 45():33-38. PubMed ID: 29032012
[TBL] [Abstract][Full Text] [Related]
13. Apomorphine: an underutilized therapy for Parkinson's disease.
Poewe W; Wenning GK
Mov Disord; 2000 Sep; 15(5):789-94. PubMed ID: 11009181
[TBL] [Abstract][Full Text] [Related]
14. Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease.
Factor SA
Neurology; 2004 Mar; 62(6 Suppl 4):S12-7. PubMed ID: 15037666
[TBL] [Abstract][Full Text] [Related]
15. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D;
Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
[TBL] [Abstract][Full Text] [Related]
16. Rotigotine for the treatment of Parkinson's disease.
Morgan JC; Sethi KD
Expert Rev Neurother; 2006 Sep; 6(9):1275-82. PubMed ID: 17009915
[TBL] [Abstract][Full Text] [Related]
17. Apomorphine in the treatment of Parkinson's disease.
Hagell P; Odin P
J Neurosci Nurs; 2001 Feb; 33(1):21-34, 37-8. PubMed ID: 11233359
[TBL] [Abstract][Full Text] [Related]
18. Sublingual apomorphine: a new pharmacological approach in Parkinson's disease?
Montastruc JL; Rascol O; Senard JM; Houin G; Rascol A
J Neural Transm Suppl; 1995; 45():157-61. PubMed ID: 8748621
[TBL] [Abstract][Full Text] [Related]
19. [Candidate patient for subcutaneous apomorphine injection].
Chacón JR; Mata M
Rev Neurol; 2012; 55 Suppl 1():S7-9. PubMed ID: 23169232
[TBL] [Abstract][Full Text] [Related]
20. Clinical usefulness of apomorphine in movement disorders.
Colosimo C; Merello M; Albanese A
Clin Neuropharmacol; 1994 Jun; 17(3):243-59. PubMed ID: 9316670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
